(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP), reducing both nasal polyp size and congestion compared to a placebo. The WAYPOINT trial … Read the full press release →
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, Amgen, AstraZeneca, chronic rhinosinusitis, Dr. Brian Lipworth, Dr. Joseph Han, Healthcare, Nasal Polyp Symptoms, partnership, safety, Sharon Barr, sustainability, tezepelumab, Tezspire, USA